June 4, 2009
Submitted by art on Fri, 2009-06-05 06:47.
A cannabis-based medicine for MS from GW Pharmaceuticals has been filed for approval in Europe, paving the way for its potential approval at the end of 2009 or early in 2010.
Clinical trials have shown GW's drug Sativex, which is sprayed under the tongue, reduces spasticity in multiple sclerosis patients who do not respond adequately to existing therapies.